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The proinﬂammatory cytokine MIF (macrophage migration inhibitory factor) is involved in physiological and pathological
processes in pregnancy. MIF maternal serum levels are increased in preeclampsia (PE). We hypothesize that pregnancy tissues are
thesourceofMIFoverexpressioninPE.MIFproteinwasstudiedinmaternalsera,placentaltissues,fetalmembranes,andumbilical
cord of 8 control and 20PE pregnancies: 10 with normal fetal growth (PE-AGA) and 10 with fetal growth restriction (PE-FGR).
MIF levels were signiﬁcantly higher in PE-AGA membranes than in controls and PE-FGR. In PE-FGR, MIF cord concentrations
were higher than in PE-AGA while MIF placental levels were lower than in controls. MIF maternal serum levels were higher in PE,
comparedtocontrols,andthediﬀerencewasmainlyduetoPE-FGRsamples.ThesedatasupportMIFinvolvementinPEpathogen-
esis and suggest that diﬀerent pregnancy tissues contribute to MIF production in PE with and without fetoplacental compromise.
1.Introduction
Preeclampsia (PE) is the most serious syndrome of human
pregnancy and it is potentially life-threatening for both
mother and fetus. In developed countries, where the diag-
nosis and management of the disease is a major aim of
prenatal care, maternal mortality attributable to PE has been
reduced. However, perinatal and long-term morbidity and
neurological sequelae, due to fetal growth restriction (FGR)
and/or preterm delivery, are still critical problems [1, 2].
Nowadays, there are no eﬀective interventions to prevent or
cure PE except for a timed and often premature delivery
[3]. This is partly due to the fact that the aetiology and the
pathogenesis of the disease are still poorly understood.
It is widely accepted that a generalized endothelial dys-
function and an exaggerated inﬂammatory response are
involved in the pathogenesis of PE [1, 2]. Furthermore, it
is assumed that an inadequate trophoblast invasion and
remodelling of maternal spiral arteries may cause or contri-
bute to the pathogenesis of the disease [4]. These tissue-
re-modelling processes are driven in part by placental
cytokines.
Macrophage migration inhibitory factor (MIF) plays
a pivotal role in inﬂammatory and immune diseases [5]
and in inﬂammatory-like reproductive events as ovulation,
menstrual cycle, and early placentation [6–8]. MIF was
originally identiﬁed as a factor released by activated T-
lymphocytes able to inhibit the random migration of macro-
phages in vitro [9]. Although macrophages and T-lym-
phocytes are the main sources of MIF, ﬁbroblast, epithelial,
and endothelial cells are also able to express and release MIF
[10, 11]. MIF is also expressed in normal trophoblast [7]
and membranes, and it is detectable in amniotic ﬂuid and in
maternal and fetal sera [12].2 Clinical and Developmental Immunology
Traditionally, the major focus of MIF research has been
on its role as a proinﬂammatory mediator. Indeed, it has
been demonstrated that MIF directly or indirectly promotes
the expression of a large panel of proinﬂammatory mole-
cules, such as tumor necrosis factor (TNF)-α, interferon γ,
interleukin- (IL-) 1β, IL-2, IL-6, IL-8, matrix metallo-pro-
teinases (MMPs), nitric oxide, and products of the arachi-
donic acid pathway [5, 13].
We have previously reported that MIF maternal serum
levels are increased in preeclamptic patients compared to
normal pregnant women [14]. Based on these ﬁndings, we
suggested that MIF might be involved in the pathogenesis of
PE.
The aim of the present study was to verify the hypothesis
that high MIF levels in preeclamptic maternal serum might
derive from the fetoplacental unit. For this purpose we
assessed the protein expression and localization of MIF
in placental tissues, fetal membranes, and umbilical cords
obtained from control and preeclamptic pregnancies.
2. Methods
We selected, classiﬁed, and managed pregnancies compli-
cated by PE and controls whose placentae, fetal membranes
and umbilical cords were processed and studied. The study
was approved by our Piedmont Regional and Hospital Ethics
Committee and informed consent was obtained from each
woman.
Exclusion criteria were, multiple pregnancies, pregnan-
cies complicated by prenatal or postnatal diagnosis of struc-
tural and/or chromosomal anomalies, and prepregnancy
diseases (chronic hypertension, diabetes, etc.).
2.1. Study Population
2.1.1. Preeclamptic Cases. Twenty consecutive pregnancies
complicated by PE were included in our study. Preeclampsia
was deﬁned by appearance of hypertension (systolic blood
pressure ≥140mmHg and/or diastolic blood pressure
≥90mmHg) accompanied by proteinuria (≥300mg/24h)
after twenty weeks of gestational age in previously normo-
tensive patients [15]. All patients had pathological uterine
Doppler ﬂow velocity waveforms (FVW), deﬁned as a
resistance index (RI) of >0.58 with or without the presence
of bilateral notching [16].
Among these patients, two subgroups were identiﬁed
based on the presence or absence of FGR: ten PE moth-
ers delivered appropriate-for-gestational-age newborns (PE-
AGA) and 10PE pregnancies were complicated by FGR (PE-
FGR).
The diagnosis of FGR was made according to the
following criteria: ultrasound measurement of the fetal
abdominal circumference below the 10th centile [17]o r
a growth velocity below the 10th percentile [18] and/or
birth-weight below the 10th centile according to our birth-
weight references [19], with abnormal FVW of the umbilical
arteries [20]. All PE pregnancies were delivered by caesarean
section.
2.1.2. Control Pregnancies. Controls were 8 normotensive
pregnancies with normal fetal growth and normal uterine
and umbilical Doppler FVWs, delivered at term by caesarean
section,becauseofbreechpresentationorpreviouscaesarean
section.
In all cases and controls, pregnancies were dated by an
ultrasound scan in the ﬁrst trimester of pregnancy.
2.1.3. Clinical Parameters. The following data were collected
for both cases and controls: maternal age at delivery, parity,
smoking habits, body mass index (BMI = kg/m2) at the
beginning of pregnancy, gestational age at birth, gestational
age at onset of PE, mode of delivery, neonatal sex and
weight at birth (neonatal weight was also expressed as Z-
score, that is, exact number of standard deviations from the
mean for gestational age, using our birth-weight references
[19]), placental weight, uterine and umbilical artery Doppler
ultrasoundvelocimetryindexes,bloodpressure,urinarypro-
tein levels, and exposure to drugs (such as antihypertensives,
corticosteroids, antibiotics, aspirin).
2.2. Tissue Samples. Immediately after delivery, normal and
pathological placentae (umbilical cord and membranes
included) were transported from the delivery room to the
laboratory and, after preliminary gross examination, two
seriesoftissuesampleswereobtained:(a)threefull-thickness
samples of placental tissue were randomly collected from
an intermediate zone between umbilical cord insertion and
periphery, two samples of fetal membranes were taken far
away from both the free edge and the placental plate, two
umbilical cord samples were dissected from an intermediate
zone between insertion and fetus; each sample was ﬁxed in
neutralbuﬀered10%formaldehydefor24hoursandembed-
ded in paraﬃn for immunohistochemistry; (b) further three
samples of placental tissue, two of fetal membranes and two
of cord tissue were collected as above described, put into
cryovials and immediately frozen in liquid nitrogen then
stored at −70◦C until tissue lysate for MIF concentration
analysis by a speciﬁc ELISA assay.
2.3. Blood Samples. Before delivery, peripheral venous blood
samples were collected in vacutainer tubes (Becton Dickin-
son) without anticoagulant, from mothers with normal and
pathological pregnancies. Serum was separated by centrifu-
gation immediately after clotting and stored at −20◦C until
assayed. Concentration of MIF in maternal serum samples
were determined by a MIF ELISA assay.
2.4. Tissue Lysate. Tissue lysates from placenta, membrane
and cord samples, from normal and pathological (PE-AGA
and PE-FGR) pregnancies, were obtained after complete
homogenization in RIPA buﬀer (50mM Tris HCl, 150mM
NaCl, 1% (vol/vol) Triton X-100, 1% (wt/vol) Na deoxy-
cholate, 0.1% (wt/vol) SDS, pH 7.5), and 3,000g centrifuga-
tion at 4◦C for 15min. After total protein evaluation, tissue
lysates were stored in aliquots at −70◦C until assayed all
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2.5. MIF ELISA. Concentration of MIF in tissue lysates as
well as in maternal sera, from preeclamptic and control
pregnancies were assayed by a colorimetric sandwich ELISA
(enzyme-linked immunosorbent assay) as reported by Ietta
et al. (2002) [12]. ELISA plates were coated with 100μL
of antihuman MIF monoclonal antibody (2.0μg/mL) (R&D
System) and incubated overnight at room temperature (RT).
The plates were washed three times with Wash Buﬀer
(10mM PBS (pH 7.4), 0.05% (v/v) Tween 20), blocked by
adding 300μL blocking solution (10mM PBS (pH 7.4), 1%
(wt/v) bovine serum albumin (BSA), 5% (wt/v) sucrose,
and 0.05% (wt/v) NaN3), and incubated at RT for 1.5h.
After three washes, the samples and the standard, human
recombinant MIF (R&D Systems), appropriately diluted in
Tris-buﬀered saline-BSA (20mM Tris-HCl, 150mM NaCl
(pH 7.3), 0.1% (wt/v) BSA, 0.05% (v/v) Tween 20), were
added in duplicate (100μL/w) and incubated for 2h at
RT. The plates were then washed three times and 100μL
of biotinylated goat antihuman MIF polyclonal antibody
(200ng/mL) (R&D Systems) was added to each well and
incubated for 2h at RT. The plates were washed again
and streptavidin horseradish peroxidase (Zymed, San Fran-
cisco, Calif, USA) was added to each well and incubated
for 20min at RT. The plates were washed and 3,3 ,5,5 -
tetramethylbenzidine (Zymed) was added. After 30min,
the reaction was stopped by adding H2SO4 (0.1M). The
absorbance was measured at 450nm using an ELISA SR 400
microplate reader (Sclavo, Siena, Italy). The MIF concentra-
tionwasexpressedaspg/mgoftotaltissueproteins,intissues
lysates, and as ng/mL, in serum samples. The sensitivity
limit was 18pg/mL. Intra- and interassay coeﬃcients of
variation (CV%) were 3.86 ± 0.95% and 9.14 ± 0.47%,
respectively.
2.6. Immunohistochemistry. Paraﬃns e c t i o n sf r o mp l a c e n t a ,
membrane and cord samples were analyzed for MIF expres-
sion by immunohistochemistry (IHC). From each sample,
serial sections of 3μm were obtained, mounted on 0.01%
poly-lysine coated glass-slides, and air-dried for 24h at
40◦C.
IHC was performed using the Strept ABComplex/AP
method. Sections were dewaxed, rehydrated, and washed in
Tris-buﬀered saline [TBS; 20mM Tris-HCl, 150mM NaCl
(pH 7.6)]. Antigen retrieval was carried out by incubating
sections in sodium citrate buﬀer (10mM, pH 6.0) in a
microwave oven at 750Watts for 5min for three times
and preincubated with normal rabbit serum to prevent
nonspeciﬁc bindings. Slides were incubated overnight at
4◦C with an anti-human MIF monoclonal antibody (R&D
System Abingdon, UK), diluted 1:100 in TBS. Slides were
washed and incubated with rabbit anti-mouse biotinylated
antibody (DAKO, Copenhagen, Denmark) at a dilution
1:200 for 40min. The alkaline phosphatase reaction was
r e v e a l e db yS i g m aF a s t( S i g m aA l d r i c h ,S t .L o u i s ,M o ,U S A )
as substrate. Sections were contrasted with Mayer’s Hema-
toxylin, mounted, and examined under a light microscope.
For each case, a negative control was obtained by using
the antibody preadsorbed with the recombinant MIF at the
concentration of 20μg per mL of diluted antibody.
2.7. Statistical Analysis. P a t i e n ta g e ,B M I ,g e s t a t i o n a la g e ,
neonatal and placental weight, birth weight Z-score, placen-
tal weight/neonatal weight ratio, blood pressure readings,
andMIFconcentrationswerereportedasmeanandstandard
deviations(SDs).Meansamonggroupswerecomparedusing
a one-way analysis of variance (ANOVA). Tamhane post
hoc tests, chosen to account for unequal variances, were
calculated to identify signiﬁcant diﬀerences between the
dependent variables at α<0.05. Categorical and nominal
values (parity, smoking habit, urinary protein levels, expo-
sure to pharmaceuticals) were analyzed by the chi-squared
test (χ2). Fisher’s exact test was used for small sample sizes.
Av a l u eo fP ≤ 0.05 was considered signiﬁcant. Statistical
evaluationwasperformedusingSPSS18forWindows(SPSS,
Chicago, Ill, USA).
3. Results
3.1. Study Population. The three study groups, controls,
PE-AGA, and PE-FGR, were comparable for maternal age,
pre-pregnancy BMI and percentage of patients receiving
antibiotics (Table 1).
All PE pregnancies diﬀered from controls for gestational
ageatdelivery,neonatalbirthweight,andneonatalweightZ-
score, blood pressure, urinary protein values and percentage
of patients receiving corticosteroids or antihypertensives
(Table 1). Smoking mothers were more frequent in PE
(statisticallysigniﬁcantinPE-FGRversuscontrolsP<0.036)
than in controls and placental weight was signiﬁcantly lower
in PE with FGR (P<0.001), while percentage of nulli-
parae was lower and placental weight/neonatal weight ratio
was signiﬁcantly higher in PE group with appropriate-for-
gestational-age newborns (PE-AGA) compared to controls
(P = 0.041 and P = 0.018, resp.) (Table 1).
T h et w os u b g r o u p so fp r e g n a n c i e sc o m p l i c a t e db yP E
did not signiﬁcantly diﬀer for percentage of nulliparae and
smoking mothers, for gestational age at delivery, gestational
a g ea to n s e to fP E ,b l o o dp r e s s u r e ,a n dp e r c e n t a g eo f
patients receiving drugs. In the PE-FGR group, neonatal
and placental weight and neonatal weight Z-score were
lower than in PE-AGA; moreover, there were diﬀerences
between the two groups in urinary protein levels, umbilical
and uterine artery Doppler ultrasound velocimetry indexes
(Table 1).
3.2. MIF Concentration in Fetoplacental Tissues and Maternal
Sera. Quantiﬁcation of MIF protein by a speciﬁc ELISA
assay revealed diﬀerences between pathological and normal
control samples as described herein (Table 2, Figure 1).
MIFconcentrationwashigherinplacentaltissuesthanin
fetal membranes and umbilical cords in control pregnancies
(Table 2). This scenario completely changed in the two sub-
groupsofpregnanciescomplicatedbyPE.MIFconcentration
was higher in fetal membranes in PE-AGA and in umbilical
cord in PE-FGR as compared to the other tissues. As for PE-
AGA,thediﬀerencewassigniﬁcantbetweenfetalmembranes
versus umbilical cord (P = 0.005) while in PE-FGR, it
was signiﬁcant between umbilical cord and fetal membranes4 Clinical and Developmental Immunology
Table 1: Clinical characteristics of control and pathological pregnancies.
Controls PE-AGA PE-FGR P value a
Number of patients 8 10 10
Maternal age at delivery (years), mean (SD) 32.8 (4.3) 34.5 (3.8) 32.5 (5.3) n.s.
Nulliparae, number and % 7∗ (87.5) 5∗ (50) 8 (80) ∗0.041
Smoking mothers, number and % 0◦ (0) 2 (20) 5◦ (50) ◦0.036
Prepregnancy BMI (Kg/m2), mean (SD) 21.4 (2.5) 24.2 (6.1) 24.4 (4.7) n.s.
Gestational age at delivery (weeks), mean (SD) 37.5∗◦ (3.2) 30.6∗ (2.6) 30.0◦ (2.5) ∗◦ <0.001
Neonatal birth weight (g), mean (SD) 3254∗◦ (439) 1360
∗∧ (309) 1001
◦∧ (277) ∗◦ <0.001; ∧0.048
Neonatal weight Z-score, mean (SD) 0.26∗◦ (0.95) −1.02
∗∧ (0.30) −2.02
◦∧ (0.58) ∗0.018; ◦ <0.001; ∧0.004
Placental weight (g), mean (SD) 541◦ (81) 428
∧ (203) 206
◦∧ (58) ◦ <0.001; ∧0.021
Placental weight/neonatal weight ratio, mean (SD) 0.17∗ (0.01) 0.31∗ (0.13) 0.23 (0.10) ∗0.018
Gestational age at onset of PE (weeks), mean (SD) n.a. 29.3 (3.1) 28.5 (3.1) n.s.
Blood pressure (mmHg), mean (SD):
Systolic 110.9∗◦ (9.4) 158.4∗ (6.6) 150.0◦ (18.9) ∗◦ <0.001
Diastolic 71.8∗◦ (7.5) 96.4∗ (9.5) 93.9◦ (9.8) ∗◦ <0.001
Proteinuria, number and %: ∗◦ ∗∧ ◦∧
<1g/24h 0 (0) 0 (0) 5 (50)
<5g/24h 0 (0) 7 (70) 3 (30) ∗◦ <0.001; ∧0.033
≥5g/24h 0 (0) 3 (30) 2 (20)
Umbilical arterial mean pulsatility index, mean (SD) n.a. 1.10 ∧ (0.17) 2.03 ∧ (0.32) ∧ <0.001
Uterine arterial mean resistance index, mean (SD) n.a. 0.67 ∧ (0.07) 0.76 ∧ (0.05) ∧0.021
Patients receiving, number and %:
Corticosteroids 1∗◦ (12.5) 9∗ (90) 10◦ (100) ∗ <0.001; ◦0.003
Antihypertensives 0∗◦ (0) 10∗ (100) 10◦ (100) ∗◦ <0.001
Antibiotics 2 (25.0) 2 (20) 0 (0) n.s.
PE: preeclampsia.
PE AGA: preeclamptic pregnancies with appropriate-for-gestational-age newborns.
PE-FGR: preeclamptic pregnancies with fetal growth restriction.
BMI: body mass index.
n.s.: not signiﬁcant.
n.a.: not available.
aP values were calculated by ANOVA test, followed by Tamhane test for pairwise comparison, or by chi-squared test (χ2).
∗Comparison between Controls and PE-AGA group.
◦Comparison between Controls and PE-FGR group.
∧Comparison between PE-AGA and PE-FGR groups.
Table 2: Concentration of MIF in normal and pathological samples.
Number of patients Placental tissue (pg/mg) Fetal membranes (pg/mg) Umbilical cord tissue (pg/mg) P valuea
Controls 8 163,8∗ (112,4) 87,7 (88,1) 72,3∗ (46,4) ∗0,034
All PE 20 119,5 (80,3) 112,8 (105,5) 85,6 (58,2) n.s.
PE-AGA 10 142,8∗ (94,6) 162,2◦ (116,7) 60,9∗◦ (48,4) ∗0,006; ◦0,005
PE-FGR 10 93,7 (51,9) 58,0◦ (54,5) 107,5◦ (58,5) ◦0,038
PE: preeclampsia.
PE-AGA: preeclamptic pregnancies with appropriate-for-gestational-age newborns.
PE-FGR: preeclamptic pregnancies with fetal growth restriction.
n.s.: not signiﬁcant.
aP values were calculated by ANOVA test, followed by Tamhane test for pair-wise comparison.
∗Comparison between placental and umbilical cord MIF concentrations.
◦Comparison between fetal membranes and umbilical cord MIF concentrations.Clinical and Developmental Immunology 5
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Figure 1: MIF ELISA assay in normal and pathological samples. (a) placenta, ∗P<0.001 (control tissues versus PE-FGR); (b) fetal
membranes, ∗P = 0.0 3( c o n t r o lt i s s u e sv e r s u sP E - A G A )a n d∗∗P = 0.004 (PE-AGA versus PE-FGR); (c) umbilical cord, ∗P = 0.047
(PE-AGA versus PE-FGR); (d) maternal serum,∗P = 0.023 (CTRL versus PE-FGR). P values were calculated by ANOVA test, followed by
Tamhane test for pair-wise comparison.
(P = 0.038) (Table 2). No signiﬁcant diﬀerences were found
in tissues when PE pregnancies were considered all together
(with or without FGR) (Table 2).
Figure 1 shows comparison in MIF concentration bet-
ween pathological and normal control pregnancies in feto-
placental tissues and maternal serum samples. PE values are
reported as percentage of controls. MIF levels in placental
tissues were signiﬁcantly lower in PE pregnancies with FGR
compared to controls (P<0.001) (Figure 1(a)). In fetal
membranes, MIF concentration was signiﬁcantly higher
in PE-AGA compared to normal membranes and PE-FGR
samples (P = 0.03 and P = 0.004, resp.) (Figure 1(b)), while
PE-FGR umbilical cord tissues had higher MIF concentra-
tion compared to levels measured in PE-AGA (P = 0.047)
and controls (not signiﬁcant) (Figure 1(c)). Finally, the
increase of MIF levels in PE maternal sera was mainly due to
PE-FGR samples, in fact MIF concentration in PE-FGR sera
resulted signiﬁcantly higher compared to control samples
(P = 0.023) (Figure 1(d)). No signiﬁcant diﬀerence was
observedforanytissuewhenPEpregnancieswereconsidered
all together except for maternal serum: MIF maternal
serum levels in PE pregnancies were signiﬁcantly higher
(5126 ± 2902ng/mL) than in controls (2467 ± 703ng/mL,
P = 0.020).
3.3. MIF Immunoreactivity in Normal and Pathological Tis-
sues. Localisation of MIF by immunohistochemistry showed
MIF protein in the villous trophoblast and fetal endothelial
cells both in controls and PE placental tissues (Figures
2(a), 2(b), and 2(c)). Diﬀerences between control and
pathological tissues were due to the appearance of a MIF
immunoreactivity in PE-FGR intervillous space, mainly at
the external border of villi (Figures 2(a) and 2(c)).
A l lc e l lt y p e so ff e t a lm e m b r a n e sw e r ep o s i t i v ef o rM I F
(Figures 2(d), 2(e), and 2(f)). PE-AGA fetal membranes
showed a stronger MIF immunostaining of epithelial cells
of amnion side and decidual cells (Figure 2(e)) compared to
controls (Figure 2(d)) and PE-FGR (Figure 2(f)).6 Clinical and Developmental Immunology
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Figure 2: MIF immunoreactivity in tissues from normal and pathological pregnancies. Reddish color indicates positive staining for MIF.
Representative images for placenta, fetal membranes, and umbilical cord from normal (a, d, g), PE-AGA (b, e, h) and PE-FGR (c, f, i)
pregnancies, respectively. (←): endothelial cells; (∧): cytotrophoblast; (◦): syncytiotrophoblast; (∗): external border of villi; a: epithelial
layer; b: mesenchymal layer; c: decidua. Original magniﬁcation: 40x for placenta panel, 20x for fetal membranes and umbilical cord
panels.
Immunohistochemistry of umbilical cord tissue sections
revealed MIF expression in all cell types, and immunos-
taining resulted stronger in external epithelial cell layer. No
distinguishable diﬀerences were observed between normal
and pathological cord tissues (Figures 2(g), 2(h), and 2(i)).
4. Discussion
Inthe presentstudy we conﬁrmedourprevious ﬁndings [14]
showing that MIF maternal serum levels are higher in PE
patients compared to normal pregnant women. Moreover,
we investigated MIF protein concentration and localization
intheplacenta,fetalmembranes,andumbilicalcordinorder
to clarify the possible role of fetoplacental tissues in deter-
mining higher MIF serum levels in PE patients. Our data on
MIF immunoreactivity in normal term placentas and fetal
membranes conﬁrm previously published works [12, 21],
whereas our observations in the umbilical cord support in
vitrostudies conducted on human umbilical vein endothelial
cells [22]. Hereinwe show forthe ﬁrsttime toour knowledge
that MIF is expressed in both control and PE fetoplacental
tissues.Clinical and Developmental Immunology 7
In this paper, we did not ﬁnd diﬀerences in MIF con-
centration in tissues obtained from normal and PE pre-
gnancies, when PE pregnancies were considered all together
(with or without FGR). Nevertheless, when PE pregnancies
with normal fetal growth and fetoplacental hemodynamics
and PE complicated by FGR (with abnormal umbilical
artery Doppler FVW) were considered separately, the picture
completely changed. Placental MIF concentration was sig-
niﬁcantly lower in PE-FGR but not in PE-AGA compared to
controls. MIF expression in fetal membranes was signiﬁ-
cantly higher in PE-AGA compared to both PE-FGR and
controls, while MIF protein was signiﬁcantly over-expressed
in PE-FGR cord tissue compared to PE-AGA and higher
compared to controls.
Noteworthy, the relative concentrations of MIF in pla-
centa, fetal membranes, and umbilical cord were diﬀerent
among groups: they were higher in the placenta of controls,
in the fetal membranes of PE-AGA, and in umbilical cord
of PE-FGR. As above reported for comparison between
normal and pathological pregnancies, diﬀerences were not
statistically signiﬁcant when PE pregnancies were considered
all together. The signiﬁcant diﬀerence in MIF maternal
serum levels is mainly due to PE-FGR cases.
As shown in our previous study on PE, the increased
serum MIF levels in PE-FGR cases were not due to β-
methasone administration because no signiﬁcant diﬀerences
were detected between before and after corticosteroids
treatment [14]. These ﬁndings are consistent with results
by Isidori et al., (2002), showing that the response of serum
cortisol to stimulation of the hypothalamo-pituitary-adrenal
axis was not associated with a corresponding rise in plasma
MIF [23].
It is well known that PE is a syndrome where similar
symptoms could origin from diﬀerent etiopathological
pathways. In 2005, Redman and Sargent [1] introduced the
concept of two diﬀerent PE diseases: placental and maternal.
Placental PE is characterized by an hypoxic placenta
subjected to oxidative stress, while maternal PE arises from
the interaction between a normal placenta and a maternal
system susceptible or suﬀering of microvascular diseases, as
well as long-term hypertension and/or diabetes [1]. Since
FGR with abnormal umbilical Doppler FVW indicates pla-
cental compromise, we used fetal growth (FGR versus AGA)
as a proxy for the deﬁnition of “placental” versus “maternal”
PE. We have recently demonstrated that the enzyme HtrA1,
involved in the physiological development of many organs,
is diﬀerentially regulated in PE-AGA and PE-FGR placentas
[24] as well as the transcription factors JunD and c-jun,
implicated in regulating cytotrophoblast proliferation and
diﬀerentiation, showing an opposite modulation in PE-
AGA and PE-FGR [25]. Moreover, Ornaghi and colleagues
observed that placental expression of anticoagulant protein
Annexin 5 was signiﬁcantly lower only in PE complicated
by FGR—but not in PE-AGA—compared to controls [26].
Often in the literature “placental PE” and “maternal PE”
a r eu s e da ss y n o n y m o u so f“ e a r l yo n s e t ”o r“ s e v e r e ”P Ea n d
“late onset” or “mild” PE, respectively. Our study population
shows that this not always true; in fact, gestational age at
onset and at delivery was the same in both PE-AGA and
PE-FGR groups. Moreover, severe PE complications, such as
HELLP syndrome, were present in both groups.
In the light of the above observations, our ﬁndings can
explain the diﬀerential role of fetoplacental compartments
for increased MIF maternal serum levels in PE.
4.1.PE-FGR. Comparedtocontrols,thesecaseswerecharac-
terized by a signiﬁcantly lower mean MIF protein content in
theplacenta.Therewerenodiﬀerenceinlocalization(mainly
in the external layer of chorionic villi, the syncytiotro-
phoblast), except for the presence of MIF immunoreactivity
in the intervillous space in pathological placentas.
The lower placental protein content could be the con-
sequence of a defective translation or increased protein
degradation, since MIF mRNA expression was not reduced
(data not shown) among groups. An alternative explanation
could be an increased MIF release in the intervillous space,
thus explaining the high maternal serum levels observed
in this subgroup of patients. A comparable phenomenon
was observed in the epithelium of bovine epididymis and
in urothelial cells of human bladder [27, 28]. In animal
models of bladder inﬂammation and injury, it was shown
that MIF protein amounts are decreased in rat urothelium
and increased in the bladder lumen [28, 29]. Moreover, it
was demonstrated that inﬂuenza A virus infection induces
a decline of intracellular MIF protein in normal human
bronchial epithelial cells, while extracellular MIF levels
increases [30]. Further studies are required to demonstrate
in vitro MIF release from PE and normal placental tissues.
ThehigherMIFlevelsthatwefoundinPE-FGRumbilical
cord were mainly localised in the epithelial and stromal cells
of Wharton’s jelly. FGR is due to abnormal development
of the villous tree, which in turn impairs feto-maternal
nutrient and gas exchanges, inducing fetal hypoxia. Since
hypoxia induces MIF production [31], the low-oxygenated
environment typical of PE-FGR placentas could be the most
likely candidate for the increased MIF levels observed in the
umbilical cord.
4.2. PE-AGA. This population was characterized by a signif-
icantly higher MIF expression in fetal membranes compared
to controls. A similar increase of MIF immunostaining was
foundinfetalmembranesofPlasmodiumfalciparuminfected
placentae [32]. Epithelial layer of membranes was previously
studied as the source of MIF in amniotic ﬂuid [12, 33]a n d
MIF levels in amniotic ﬂuid were increased in inﬂammatory
conditions[34,35].Itisplausiblethatfetalmembranescould
be the source of the slight increase in MIF maternal serum
levels observed in PE-AGA.
In conclusion, our study further supports the evidence
that MIF-related inﬂammation plays a pivotal role in the
pathogenesis of PE. Our data provided new insights on the
tissues responsible for the increased maternal MIF serum
levels in PE, although it does not answer the question
whether increased maternal MIF serum levels are the cause
ortheconsequenceofinﬂammation.Indeed,MIFwasshown
to upregulate and to be upregulated by proinﬂammatory
stimuli [5, 36]. Of clinical relevance, we were able to8 Clinical and Developmental Immunology
discriminate between placental and maternal preeclampsia
on the base of MIF source within fetoplacental tissues.
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